IMMUNE CHECKPOINT INHIBITOR
Clinical trials for IMMUNE CHECKPOINT INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITOR trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Mushroom-Derived pill plus radiation shows promise for tough cancers
Disease control Not yet recruitingThis study tests whether a combination of PRaG-1 tablets (made from a natural fungus), targeted radiation, immune-boosting shots, and immunotherapy can help people with advanced solid tumors that have not responded to standard treatments. About 65 participants will receive all tr…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
AI-Guided immunotherapy aims to stop liver cancer recurrence
Disease control Not yet recruitingThis study tests whether a deep learning model can identify which liver cancer patients benefit from immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 adults who had their liver cancer completely removed will be followed to see if the A…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Pain pills vs. cancer treatment: new study investigates opioid impact on immunotherapy
Knowledge-focused Not yet recruitingThis study looks at how well immunotherapy works in people with advanced lung cancer who also have moderate to severe pain and take opioid painkillers. Researchers want to see if the level of pain control or the use of opioids changes how effective the cancer treatment is. About …
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated May 19, 2026 11:46 UTC